3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
11
Breast Neoplasms
8
Prostatic Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Melanoma
5
COVID-19
4
Multiple Myeloma
3
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Recurrence
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Leukemia
2
Glioblastoma
2
Cholangiocarcinoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Urologic Diseases
1
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma, Clear Cell
1
Sarcoma
1
Interventions
telitacicept
3
fludarabine
3
Prednisone
3
Cyclophosphamide
3
Specimen Handling
2
Nivolumab
2
Antilymphocyte Serum
2
thymoglobulin
1
remdesivir
1
prednylidene
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
cabozantinib
1
Vitamin D
1
Valsartan
1
Pyridostigmine Bromide
1
Population Groups
1
Platinum Compounds
1
Plasma Exchange
1
Peripheral Blood Stem Cell Transplantation
1
Music Therapy
1
Melphalan
1
Ipilimumab
1
Infliximab
1
Immunoglobulins, Intravenous
1
Hydroxychloroquine
1
Fish Oils
1
Fatty Acids, Omega-3
1
Etoposide
1
Etanercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Autoimmune Diseases
×
Hydroxychloroquine
×
Clear all
NCT02765594
2017-09-20
HCQIgAN
Peking Union Medical College Hospital
Phase 4
Unknown
98 enrolled